DR. DATSONS LABS | CADILA HEALTHCARE | DR. DATSONS LABS/ CADILA HEALTHCARE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | 28.3 | - | View Chart |
P/BV | x | 0.2 | 4.6 | 3.6% | View Chart |
Dividend Yield | % | 0.0 | 0.8 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
CADILA HEALTHCARE Mar-20 |
DR. DATSONS LABS/ CADILA HEALTHCARE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 352 | 35.7% | |
Low | Rs | 31 | 207 | 15.0% | |
Sales per share (Unadj.) | Rs | 133.0 | 139.2 | 95.5% | |
Earnings per share (Unadj.) | Rs | 0.2 | 11.8 | 1.3% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 18.6 | 35.6% | |
Dividends per share (Unadj.) | Rs | 0 | 3.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.3 | 0.0% | |
Book value per share (Unadj.) | Rs | 128.8 | 101.4 | 127.1% | |
Shares outstanding (eoy) | m | 31.66 | 1,023.74 | 3.1% | |
Bonus/Rights/Conversions | FCCB | - | - | ||
Price / Sales ratio | x | 0.6 | 2.0 | 29.3% | |
Avg P/E ratio | x | 516.1 | 23.7 | 2,173.2% | |
P/CF ratio (eoy) | x | 11.8 | 15.0 | 78.7% | |
Price / Book Value ratio | x | 0.6 | 2.8 | 22.0% | |
Dividend payout | % | 0 | 29.8 | 0.0% | |
Avg Mkt Cap | Rs m | 2,477 | 286,033 | 0.9% | |
No. of employees | `000 | NA | 13.4 | 0.0% | |
Total wages/salary | Rs m | 56 | 24,145 | 0.2% | |
Avg. sales/employee | Rs Th | NM | 10,632.7 | - | |
Avg. wages/employee | Rs Th | NM | 1,801.2 | - | |
Avg. net profit/employee | Rs Th | NM | 898.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 142,531 | 3.0% | |
Other income | Rs m | 79 | 1,139 | 6.9% | |
Total revenues | Rs m | 4,289 | 143,670 | 3.0% | |
Gross profit | Rs m | 569 | 24,198 | 2.3% | |
Depreciation | Rs m | 204 | 6,965 | 2.9% | |
Interest | Rs m | 430 | 3,418 | 12.6% | |
Profit before tax | Rs m | 13 | 14,954 | 0.1% | |
Minority Interest | Rs m | 0 | 288 | 0.0% | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6 | 3,198 | 0.2% | |
Profit after tax | Rs m | 5 | 12,044 | 0.0% | |
Gross profit margin | % | 13.5 | 17.0 | 79.5% | |
Effective tax rate | % | 48.0 | 21.4 | 224.6% | |
Net profit margin | % | 0.1 | 8.5 | 1.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 87,154 | 7.9% | |
Current liabilities | Rs m | 6,711 | 82,694 | 8.1% | |
Net working cap to sales | % | 3.3 | 3.1 | 107.0% | |
Current ratio | x | 1.0 | 1.1 | 96.9% | |
Inventory Days | Days | 161 | 71 | 225.2% | |
Debtors Days | Days | 318 | 94 | 339.5% | |
Net fixed assets | Rs m | 3,673 | 133,236 | 2.8% | |
Share capital | Rs m | 317 | 1,024 | 30.9% | |
"Free" reserves | Rs m | 3,761 | 102,733 | 3.7% | |
Net worth | Rs m | 4,078 | 103,757 | 3.9% | |
Long term debt | Rs m | 1,671 | 32,146 | 5.2% | |
Total assets | Rs m | 12,633 | 236,866 | 5.3% | |
Interest coverage | x | 1.0 | 5.4 | 19.2% | |
Debt to equity ratio | x | 0.4 | 0.3 | 132.3% | |
Sales to assets ratio | x | 0.3 | 0.6 | 55.4% | |
Return on assets | % | 3.4 | 6.5 | 52.8% | |
Return on equity | % | 0.1 | 11.6 | 1.0% | |
Return on capital | % | 7.7 | 13.7 | 55.9% | |
Exports to sales | % | 22.9 | 0 | - | |
Imports to sales | % | 14.3 | 0 | - | |
Exports (fob) | Rs m | 964 | NA | - | |
Imports (cif) | Rs m | 602 | NA | - | |
Fx inflow | Rs m | 964 | 52,752 | 1.8% | |
Fx outflow | Rs m | 607 | 14,504 | 4.2% | |
Net fx | Rs m | 357 | 38,248 | 0.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 25,054 | 5.4% | |
From Investments | Rs m | -2,256 | -10,123 | 22.3% | |
From Financial Activity | Rs m | -1,200 | -10,942 | 11.0% | |
Net Cashflow | Rs m | -2,111 | 3,989 | -52.9% |
Indian Promoters | % | 4.5 | 74.8 | 6.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 8.3 | - | |
FIIs | % | 1.4 | 5.9 | 22.9% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 11.0 | 855.5% | |
Shareholders | 20,807 | 44,069 | 47.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. DATSONS LABS With: UNICHEM LAB AUROBINDO PHARMA STERLING BIOTECH GLENMARK PHARMA VENUS REMEDIES
Compare DR. DATSONS LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More